Literature DB >> 18566170

Invasive breast cancer: predicting disease recurrence by using high-spatial-resolution signal enhancement ratio imaging.

Ka-Loh Li1, Savannah C Partridge, Bonnie N Joe, Jessica E Gibbs, Ying Lu, Laura J Esserman, Nola M Hylton.   

Abstract

PURPOSE: To retrospectively evaluate high-spatial-resolution signal enhancement ratio (SER) imaging for the prediction of disease recurrence in patients with breast cancer who underwent preoperative magnetic resonance (MR) imaging.
MATERIALS AND METHODS: This retrospective study was approved by the institutional review board and was HIPAA compliant; informed consent was waived. From 1995 to 2002, gadolinium-enhanced MR imaging data were acquired with a three time point high-resolution method in women undergoing neoadjuvant therapy for invasive breast cancers. Forty-eight women (mean age, 49.1 years; range, 29.7-72.4 years) were divided into recurrence-free or recurrence groups. Volume measurements were tabulated for SER values between set ranges; cutoff criteria were defined to predict disease recurrence after surgery. Wilcoxon rank sum tests and the multivariate Cox proportional hazards regression model were used for evaluation.
RESULTS: Breast tumor volume calculated from the number of voxels with SER values above a threshold corresponding to the upper limit of mean redistribution rate constant in benign tumors (0.88 minutes(-1)) and the volume of cancerous breast tissue infiltrating into the parenchyma were important predictors of disease recurrence. Seventy-five percent of patients with recurrence and 100% of deceased patients were identified as being at high risk for recurrence. Thirty percent of patients with recurrence and 67% of deceased patients were identified as having high risk before chemotherapy. No patients in the recurrence-free group were misidentified as likely to have recurrence. All three prechemotherapy parameters (total tumor volume, tumor volumes with high and low SER) and the postchemotherapy tumor volume with high SER were significantly different between the two groups. The multivariate Cox proportional hazards regression showed that, of the three prechemotherapy covariates, only the low SER and high SER tumor volumes (P = .017 and .049, respectively) were significant and independent predictors of tumor recurrence. Tumor volume with high SER was the only significant postchemotherapy covariate predictor (P = .038).
CONCLUSION: High-spatial-resolution SER imaging may improve prediction for patients at high risk for disease recurrence and death. (c) RSNA, 2008.

Entities:  

Mesh:

Year:  2008        PMID: 18566170      PMCID: PMC5410941          DOI: 10.1148/radiol.2481070846

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  34 in total

1.  Dynamic breast MR imaging: are signal intensity time course data useful for differential diagnosis of enhancing lesions?

Authors:  C K Kuhl; P Mielcareck; S Klaschik; C Leutner; E Wardelmann; J Gieseke; H H Schild
Journal:  Radiology       Date:  1999-04       Impact factor: 11.105

2.  Dynamic bilateral contrast-enhanced MR imaging of the breast: trade-off between spatial and temporal resolution.

Authors:  Christiane K Kuhl; Hans H Schild; Nuschin Morakkabati
Journal:  Radiology       Date:  2005-09       Impact factor: 11.105

3.  MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival.

Authors:  Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton
Journal:  AJR Am J Roentgenol       Date:  2005-06       Impact factor: 3.959

Review 4.  Modeling tracer kinetics in dynamic Gd-DTPA MR imaging.

Authors:  P S Tofts
Journal:  J Magn Reson Imaging       Date:  1997 Jan-Feb       Impact factor: 4.813

5.  Pathophysiologic basis of contrast enhancement in breast tumors.

Authors:  M V Knopp; E Weiss; H P Sinn; J Mattern; H Junkermann; J Radeleff; A Magener; G Brix; S Delorme; I Zuna; G van Kaick
Journal:  J Magn Reson Imaging       Date:  1999-09       Impact factor: 4.813

Review 6.  A review of 1H nuclear magnetic resonance relaxation in pathology: are T1 and T2 diagnostic?

Authors:  P A Bottomley; C J Hardy; R E Argersinger; G Allen-Moore
Journal:  Med Phys       Date:  1987 Jan-Feb       Impact factor: 4.071

7.  Dynamic MR imaging of the breast combined with analysis of contrast agent kinetics in the differentiation of primary breast tumours.

Authors:  S Mussurakis; D L Buckley; P J Drew; J N Fox; P J Carleton; L W Turnbull; A Horsman
Journal:  Clin Radiol       Date:  1997-07       Impact factor: 2.350

8.  Contrast-Enhanced Magnetic Resonance Imaging to Assess Tumor Histopathology and Angiogenesis in Breast Carcinoma.

Authors:  Laura Esserman; Nola Hylton; Tracy George; Noel Weidner
Journal:  Breast J       Date:  1999-01       Impact factor: 2.431

Review 9.  Gadolinium-enhanced breast MRI.

Authors:  F Kelcz; G Santyr
Journal:  Crit Rev Diagn Imaging       Date:  1995

10.  Correlation of dynamic contrast enhancement MRI parameters with microvessel density and VEGF for assessment of angiogenesis in breast cancer.

Authors:  Min-Ying Su; Yun-Chung Cheung; John P Fruehauf; Hon Yu; Orhan Nalcioglu; Eugene Mechetner; Ainura Kyshtoobayeva; Shin-Cheh Chen; Swei Hsueh; Christine E McLaren; Yung-Liang Wan
Journal:  J Magn Reson Imaging       Date:  2003-10       Impact factor: 4.813

View more
  26 in total

1.  Background parenchymal enhancement in the contralateral normal breast of patients undergoing neoadjuvant chemotherapy measured by DCE-MRI.

Authors:  Jeon-Hor Chen; Hon Yu; Muqing Lin; Rita S Mehta; Min-Ying Su
Journal:  Magn Reson Imaging       Date:  2013-08-29       Impact factor: 2.546

2.  Association between serial dynamic contrast-enhanced MRI and dynamic 18F-FDG PET measures in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer.

Authors:  Savannah C Partridge; Risa K Vanantwerp; Robert K Doot; Xiaoyu Chai; Brenda F Kurland; Peter R Eby; Jennifer M Specht; Lisa K Dunnwald; Erin K Schubert; Constance D Lehman; David A Mankoff
Journal:  J Magn Reson Imaging       Date:  2010-11       Impact factor: 4.813

3.  Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer.

Authors:  Jia Wu; Bailiang Li; Xiaoli Sun; Guohong Cao; Daniel L Rubin; Sandy Napel; Debra M Ikeda; Allison W Kurian; Ruijiang Li
Journal:  Radiology       Date:  2017-07-14       Impact factor: 11.105

4.  Ductal Carcinoma in Situ: Quantitative Preoperative Breast MR Imaging Features Associated with Recurrence after Treatment.

Authors:  Jing Luo; Brian S Johnston; Averi E Kitsch; Daniel S Hippe; Larissa A Korde; Sara Javid; Janie M Lee; Sue Peacock; Constance D Lehman; Savannah C Partridge; Habib Rahbar
Journal:  Radiology       Date:  2017-09-14       Impact factor: 11.105

5.  PET tumor metabolism in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy: value of static versus kinetic measures of fluorodeoxyglucose uptake.

Authors:  Lisa K Dunnwald; Robert K Doot; Jennifer M Specht; Julie R Gralow; Georgiana K Ellis; Robert B Livingston; Hannah M Linden; Vijayakrishna K Gadi; Brenda F Kurland; Erin K Schubert; Mark Muzi; David A Mankoff
Journal:  Clin Cancer Res       Date:  2011-03-01       Impact factor: 12.531

6.  Early assessment of breast cancer response to neoadjuvant chemotherapy by semi-quantitative analysis of high-temporal resolution DCE-MRI: preliminary results.

Authors:  Richard G Abramson; Xia Li; Tamarya Lea Hoyt; Pei-Fang Su; Lori R Arlinghaus; Kevin J Wilson; Vandana G Abramson; A Bapsi Chakravarthy; Thomas E Yankeelov
Journal:  Magn Reson Imaging       Date:  2013-08-15       Impact factor: 2.546

7.  Dynamic contrast-enhanced and diffusion-weighted MR imaging in the characterisation of small, non-palpable solid testicular tumours.

Authors:  Lucia Manganaro; Matteo Saldari; Carlotta Pozza; Valeria Vinci; Daniele Gianfrilli; Ermanno Greco; Giorgio Franco; Maria Eleonora Sergi; Michele Scialpi; Carlo Catalano; Andrea M Isidori
Journal:  Eur Radiol       Date:  2017-08-30       Impact factor: 5.315

8.  Microcirculatory fraction (MCF(I)) as a potential imaging marker for tumor heterogeneity in breast cancer.

Authors:  Xiangyu Yang; Ewa Mrozek; Maryam Lustberg; Guang Jia; Steffen Sammet; Christina Sammet; Charles Shapiro; Michael V Knopp
Journal:  Magn Reson Imaging       Date:  2012-08-11       Impact factor: 2.546

9.  Kinetic curves of malignant lesions are not consistent across MRI systems: need for improved standardization of breast dynamic contrast-enhanced MRI acquisition.

Authors:  Sanaz A Jansen; Akiko Shimauchi; Lindsay Zak; Xiaobing Fan; Abbie M Wood; Gregory S Karczmar; Gillian M Newstead
Journal:  AJR Am J Roentgenol       Date:  2009-09       Impact factor: 3.959

10.  Triple-negative and non-triple-negative invasive breast cancer: association between MR and fluorine 18 fluorodeoxyglucose PET imaging.

Authors:  Marjan S Bolouri; Sjoerd G Elias; Dorota J Wisner; Spencer C Behr; Randall A Hawkins; Sachiko A Suzuki; Krysta S Banfield; Bonnie N Joe; Nola M Hylton
Journal:  Radiology       Date:  2013-07-22       Impact factor: 11.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.